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http://www.ro-journal.com/content/9/1/73RESEARCH Open AccessIntensity-modulated stereotactic radiosurgery for
arteriovenous malformations: guidance for
treatment planning
Marcus Sonier1,3*, Ermias Gete1, Chris Herbert1, Michael McKenzie1, James Murphy2 and Vitali Moiseenko1,2Abstract
Background: Stereotactic Radiosurgery (SRS) is a common tool used to treat Arteriovenous Malformations (AVMs)
in anatomical locations associated with a risk of surgical complications. Despite high rates of clinical effectiveness, SRS
carries a risk of toxicity as a result of radiation injury to brain tissue. The use of intensity-modulated radiotherapy (IMRT)
has increased because it may lead to improved PTV conformity and better Normal Tissue (NT) sparing compared to 3D
Conformal Radiotherapy (3DCRT). The aim of this study was twofold: 1) to develop simple patient stratification rules for
the recommendation of IMRT planning strategies over 3DCRT in the treatment of AVMs with SRS; and 2) to estimate
the impact of IMRT in terms of toxicity reduction using retrospectively reported data for symptomatic radiation injury
following SRS.
Methods: Thirty-one AVM patients previously treated with 3DCRT were replanned in a commercial treatment planning
system using 3DCRT and static gantry IMRT with identical beam arrangements. The radiotherapy planning metrics
analyzed included AVM volume, diameter, and volume to surface area ratio. The dosimetric endpoints analyzed
included conformity index improvements and NT sparing measured by the maximum NT dose, and the volume of
surrounding tissue that received 7Gy and 12Gy.
Results: Our analysis revealed stratified subsets of patients for IMRT that were associated with improved conformity,
and those that were associated with decreased doses to normal tissue. The stratified patients experienced an
improvement in conformity index by −6-68%, a reduction in the maximum NT dose by −0.5-12.3%, a reduction in the
volume of NT receiving 7Gy by 1-8 cc, and a reduction in the volume of NT receiving 12Gy by 0–3.7 cc. The reduction
in NT receiving 12Gy translated to a theoretical decrease in the probability of symptomatic injury by 0–9.3%.
Conclusions: This work indicates the potential for significant patient improvements when treating AVMs and provides
rules to predict which patients are likely to benefit from IMRT.
Keywords: Stereotactic radiosurgery, Intensity modulated radiotherapy (IMRT), Arteriovenous malformation (AVM),
Treatment planning, Patient stratificationBackground
Arteriovenous Malformations (AVMs) can be treated using
a variety of techniques including surgery, embolization, or
Stereotactic Radiosurgery (SRS), any of which can obtain
optimal results. Among these modalities, SRS is often the
treatment of choice for AVMs in anatomical locations* Correspondence: marcus.sonier@sunnybrook.ca
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reproduction in any medium, provided the orassociated with a risk of surgical complications [1].
Through the application of SRS, complete nidal obliteration
is the desired curative outcome, and typically takes up to
2–3 years to manifest with a success rate of 60-90% [1-8].
Additionally, Normal Tissue (NT) toxicity may arise
from SRS with complications reported to occur in 3-7% of
patients [1,3,6,9-12].
AVM obliteration depends principally on the minimum
dose to the Planning Target Volume (PTV), typically
greater than 18Gy [8,13-15]. Two distinct dosimetric
factors have consistently shown to be strong predictors ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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and conformity of the dose distribution encompassing the
PTV [4,6,10,12,16-18]. A recent Quantitative Analysis of
Normal Tissue Effects in the Clinic (QUANTEC) report
summarized toxicity data from a selection of studies and
demonstrated that V10 and V12 are particularly strong
and consistently observed predictors of toxicity, with
V12 serving as a predictor of choice [18]. Similarly, a
strong correlation between various volumetric endpoints
and subsequent brain injury has also been reported at
lower doses such as V7 [17]. Radiation doses with SRS
plans balance the risk of symptomatic brain injury with
the likelihood of nidus obliteration.
Optimizing radiation plans to minimize the risk of
toxicity is particularly difficult to achieve for complex-
shaped AVMs. Intensity Modulated Radiotherapy (IMRT)
has been proposed as a means to improve plan conformity
and thereby reduce the risk of complications [13]. Despite
the potential benefit of IMRT, its implementation is
costly and resource-intensive. In addition to planning,
patient-specific Quality Assurance (QA) is required,
usually involving ion chamber measurements at the
isocenter and a comparison of planned and delivered
fluence maps. Furthermore, with the introduction of
image guided frameless SRS, it has become common
practice to treat stereotactic patients with IMRT.
Given the resources involved in using IMRT, we sought
to develop a decision tool that identified the subset of AVM
patients who would benefit the most from IMRT. The
specific aims of this study are twofold: 1) to develop simple
patient stratification rules for the recommendation of
IMRT planning strategies over 3DCRT in the treatment of
AVMs with SRS, and 2) to estimate the impact of IMRT in
terms of toxicity reduction using retrospectively reported
data for symptomatic radiation injury following SRS.
Methods
CT, MR, and Angiogram image sets for thirty-one AVM
patients previously treated at the BC Cancer Agency were
used in this study. These image sets were transferred to an
up-to-date version of the iPlan (BrainLAB AG, Heimstetten,
Germany) treatment planning system software for use with
the BrainLab microMLC. The CT and Angiogram images
were localized and fused to the MR images, followed by
manual contouring of each patient’s AVM by an oncologist
specializing in SRS. Next, a PTV was constructed by
expanding the AVM contour by a 1 mm margin in
3-dimensions, and treatment plans utilizing 3DCRT and
static gantry IMRT were produced as described below. The
study was approved by the institutional ethics committee.
A. 3D Conformal radiotherapy
In 3DCRT, plans used for patient treatment were consulted
as a guideline for the positioning and number of beams.With these guidelines, single isocenter treatment plans
were produced with PTV coverage as the primary objective
while respecting dose to Organs At Risk (OARs). Dose
was prescribed to the isocenter of the PTV. Multi-Leaf
Collimator (MLC) shapes were manually adjusted to
achieve PTV coverage so that the 80% isodose line
encompassed the PTV, minimizing spillage of the 80%
isodose to surrounding NT. Multiple fields (typically at
least 10) were used to minimize the beam overlap effect
and MLC shapes were manipulated manually to achieve
the planning objectives. PTV coverage was optimized and
verified in the axial, coronal, and sagittal slice views on
both CT and MR image sets and in the Dose-Volume
Histogram (DVH) view.
B. Intensity modulated radiotherapy
The beam arrangement with IMRT was identical to
those used with 3DCRT. The dose to the PTV margin,
corresponding to the 80% isodose in the 3DCRT plans,
was specified as a hard constraint. The dose optimization
settings were selected as follows: PTV dose calculation
grid size = 1 mm, OAR dose calculation grid size = 2 mm,
Beamlet size max = 1 mm, Step-and-Shoot leaf sequencing,
and Tongue-and-Groove Optimization for MLC leaf
positioning. Initially, a sample plan was generated to
determine the volume of NT enclosed by the 7Gy
isodose surface. This 7Gy isodose surface was used to
construct a normal tissue OAR sphere that fully
enclosed the 7 and 12Gy isodose surfaces, with the
PTV removed. Figure 1 illustrates the OAR sphere
encompassing the target volume. This OAR sphere
was used to apply NT constraints at the 7 and 12Gy
isodose volumes during IMRT optimization. For each
patient, four IMRT plans were generated using utilities
available in the iPlan treatment planning system: PTV Only,
OAR Low, OAR Medium, and OAR High. PTV Only
represented an IMRT plan that optimized solely with the
PTV, ignoring the surrounding OAR. OAR Low, Medium,
and High represented plans that attempted to limit
dose to the OAR sphere with increasing weighting
(from low to high). With the OAR Low, Medium, and
High plans, the NT constraints were applied at the
dose-volumes of interest (7 and 12Gy) and were patient
specific, depending on the initial dose the NT received as a
result of the PTV's size and shape. Therefore, the NT
constraints were set through an iterative process such that,
through the IMRT optimization algorithm, maximum NT
sparing was achieved without sacrificing PTV coverage.
With each IMRT plan, greater than 99.9% of the PTV
volume received the prescribed dose.
C. Plan comparisons
The AVM metrics obtained from each patient included
the volume of the PTV, the maximum PTV diameter,
Figure 1 OAR sphere. A representative patient’s PTV encompassed by an OAR sphere (bright green). The sphere fully contains the 7Gy isodose
(blue) in order to allow IMRT constraints to adequately restrict dose to NT.
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area of the PTV (Vol./SA). Treatment planning systems
typically do not provide tools to calculate the surface
area. Our goal was also to provide a solution which can be
implemented using tools routinely available in planning
systems, such as expanding volumes by a margin. The
surface area was therefore estimated from the change in
volume from the 1 mm expansion of the AVM to the PTV
divided by 1 mm. The accuracy of this approximation
improves as the expansion margin decreases. However, by
trial-and-error method we established that that margins
smaller than the slice thickness lead to irregularities on the
expanded contour. Conversely, a larger margin makes this
method inaccurate for complex-shaped lesions. The 1 mm
margin has been selected as an acceptable compromise. In
the narrative below SA is used in the context of the
used approximation. The Vol./SA measurement attempted
to characterize the complexity of the shape of the PTV.
Shapes well approximated by a sphere have Vol./SA
measurements comparable to expected for a sphere
with the same volume, while complex shapes have
low Vol./SA measurements compared to a sphere with
the same volume.
The dosimetric endpoints analyzed included the
conformity index which was defined as the volume
enclosed by the prescription dose divided by the PTV
volume. Additional endpoints included the maximum
NT dose, and the volume of NT receiving 7 and
12Gy. Plots were constructed to show the benefits of each
of the four IMRT plans compared to 3DCRT plans as
measured by each dosimetric endpoint defined above. The
individual plots were assessed to find any visual pattern of
benefits that clearly indicated potential stratification rulesthat could be used to isolate patients who would benefit
from IMRT. Statistical analysis was then performed via
the one-tailed t-test to determine the significance of
two aspects of the results: the benefit of PTV Only
IMRT vs. OAR Low IMRT for all patients and the patient
improvements in the stratified subset vs. the unstratified
subset for each dosimetric endpoint. When comparing
PTV Only IMRT vs. OAR Low IMRT, all 31 patients were
considered whereas when analysing the stratification
results, for conformity index, NT max dose, V7, and V12,
the 31 patients were split into two groups (no patients
were omitted) following the established stratification rules.
Results
Patient treatment characteristics are shown in Table 1.
The prescribed dose was delivered in a single fraction
and varied by the size, shape, and location of the PTV.
Thus, larger PTVs received lower dose prescriptions, with a
reduced probability of AVM obliteration, as a compromise
for avoiding NT complications from irradiating larger
volumes of normal brain tissue. Anatomic locations of the
AVMs varied widely throughout the brain, occurring next
to relatively deep and important structures such as the
brainstem, optic nerves, and thalamus as well as out
towards the brain’s periphery: in the frontal, temporal,
parietal, and occipital regions.
First, we compared the difference between 3DCRT and
each of the four IMRT plans for all patients in this study.
These results are shown in Figure 2 with the dosimetric
endpoints of conformity index, NT max dose, V7, and
V12 depicted in A-D, respectively. With conformity
index, each of the IMRT plans on average produced
more conformal plans than 3DCRT, and of the IMRT
Table 1 Patient summary
Patient summary
Number of Patients 31
PTV Diameter (cm) Range: 0.99-5.38
Median: 2.71
PTV Volume (cc) Range: 0.334-26.720
Median: 2.666
Prescribed Dose (Gy) Range: 12–25
Median: 20
Summary of patient data concerning lesion characteristics and prescribed
treatment dose.
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over 3DCRT. With NT max dose, only the PTV Only
IMRT plan had lower maximum dose than 3DCRT.
OAR Low, Medium, and High IMRT plans more
often had higher maximum NT doses. With the V7
dosimetric endpoint, the PTV Only and OAR High
IMRT plans increased the NT volume receiving 7Gy,
whereas the OAR Low and OAR Medium plans decreased
the NT volume receiving 7Gy. With the V12 dosimetric
endpoint, each of the IMRT plan types on average reduced
the NT volume receiving 12Gy, compared to 3DCRT, with
the OAR Low and OAR Medium plans providing the
greatest overall benefit.
Next, we explored whether characteristics of the
AVM were associated with circumstances where IMRT
was consistently superior to 3DCRT. Figure 2A-D
demonstrates select 2×2 plots that show conditions where
IMRT outperforms 3DCRT for each of the dosimetric
endpoints analyzed. Figure 3 shows the distribution of
improvements in conformity index for IMRT compared to
3DCRT with the PTV Only IMRT plan. IMRT was
consistently associated with an improved conformity index
when Vol./SA <0.25 cm and PTV diameter <2.25 cm.
Figure 4 shows the distribution of reduction in maximum
NT dose for IMRT compared to 3DCRT with the PTV
Only IMRT plan. In this case, patients with PTV diameters
greater than 2.5 cm appear to benefit the most from IMRT.
Figures 5 and 6 show the distribution of improvements in
V7 and V12, respectively, with OAR Low IMRT plans. With
V7 (Figure 5), patients whose PTV volumes are >5 cc and
PTV diameters >3 cm had the largest degree of NT
sparing with IMRT. With V12 (Figure 6), patients with
PTV diameters >3 cm received the largest NT sparing
with IMRT. Finally, Table 2 summarizes the information
contained in Figures 3, 4, 5, and 6 by presenting simple
stratification rules that demonstrate the AVM characteristics
where IMRT outperforms 3DCRT.
Finally, statistical analysis revealed p-values of <0.001 for
conformity index, NT max dose, and V7 while V12 had a
p-value of 0.024 when comparing PTV Only IMRTbenefits against OAR Low IMRT benefits. Comparing
stratified patients vs. unstratified patients for the plan type
of choice for each dosimetric endpoint revealed p-values of
0.023, 0.400, 0.001, and 0.002 for conformity index
(PTV Only IMRT), NT max dose (PTV Only IMRT), V7
(OAR Low IMRT), and V12 (OAR Low IMRT), respectively.
Discussion
The first intent of this study was to identify characteristics
of an AVM that predicted improvement with IMRT
compared to 3DCRT. This allows a treatment team to
identify patients who are most likely to benefit from
IMRT. This study also demonstrates the tradeoffs of
IMRT and 3DCRT. Stratification criteria such as these
allow a physician to choose which dosimetric endpoint
carries the most importance for a given patient, and then
use the characteristics of the individual AVM to determine
whether IMRT is likely to generate a superior plan
compared to 3DCRT. This could potentially reduce
treatment time, reduce resource use, and improve plan
quality which impacts patient care.
The safe and effective treatment of AVMs with SRS
balances dose to the PTV with dose to surrounding
normal tissues. The importance of dose to the periphery
of the AVM was demonstrated by Herbert et al. who
found that dose to the PTV margin >20Gy was strongly
associated with nidus obliteration [14]. Because the
incidence of symptomatic brain injury correlates with
dose to surrounding NT, plan conformity is of the utmost
importance. This result has also been validated in a study
by Friedman et al. who found that improved PTV
conformity correlates with a reduced incidence of
complications [10]. Thus, the choice of the optimal
radiation planning modality to improve the conformity
index can significantly reduce the probability of SRS
induced complications. In our study, this level of improve-
ment in treatment plans was found to occur more so in
patients with a large PTV surface area compared to their
volume (small Vol./SA ratio, <0.25 cm), and small PTV
diameters (<2.25 cm).
In addition to the importance of conformity index,
maximum dose to NT should not be overlooked. Unlike
other cancerous stereotactic targets, the target volume
in an AVM may contain regions of normal brain tissue
intermittently spaced between the blood vessels. The
normal tissue surrounding and within the PTV is at risk
of toxicity with SRS. Therefore, it is desirable to minimize
hotspots in these areas by maintaining the dose to the
PTV as close to the prescribed dose as possible. The
IMRT plans in this study accomplished this by reducing
the max dose to NT and the PTV, increasing the steepness
of the dose fall off gradient at the edges of the PTV,
and reducing and distributing any hot spots diffusely
throughout the PTV compared to 3DCRT. This reduction
-0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8
Conformity index
-30% -20% -10% 0% 10% 20% 30%
Normal tissue max dose
-10 -5 0 5 10
V7 (cc)
-5 0 5
V12 (cc)
3DCRT better IMRT better
    PTV Only
    OAR Low
    OAR Medium
    OAR High
    PTV Only
    OAR Low
    OAR Medium
    OAR High
    PTV Only
    OAR Low
    OAR Medium
    OAR High
    PTV Only
    OAR Low
    OAR Medium
    OAR High
A
D
C
B
Figure 2 Endpoint Comparisons for 3DCRT vs. IMRT. Points represent the median difference between IMRT and 3DCRT plans for conformity
index (A), normal tissue maximum dose (B), V7 (C), and V12 (D). For each patient, four different IMRT plans were generated including PTV Only
(blue diamond), OAR Low (red square), OAR Medium (green triangle), and OAR High (purple circle). Positive values represent circumstances where
IMRT outperforms 3DCRT, and negative values represent circumstances where 3DCRT outperforms IMRT. Error bars represent the range of values.
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reduce the risk of symptomatic brain injury. Along the
lines of maximum dose, the 12Gy isodose volume has
been investigated by numerous groups and consistently
shown to strongly correlate with symptomatic brain
injury. This 12Gy cut-off may not be the only predictor as
volumes receiving doses of at least 7Gy among other
radiation doses also correlate with a risk of brain
injury [17,19]. We found similar stratification rulesassociated with larger PTV diameters that predict superior
plans with IMRT with respect to NT max dose, V7, and
V12. This suggests that reduction in one normal tissue
constraint does not come at a cost of increase in another
with IMRT planning. To determine the significance of our
rules, we performed statistical analysis on the two patient
groups separated via stratification for each endpoint. The
resultant p-values obtained when considering conformity
index, NT max dose, V7, and V12, for the suggested IMRT
1 2 3 4 5
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Figure 3 Conformity Index (PTV Only IMRT). Distribution of patient improvements regarding PTV conformity when comparing PTV Only IMRT
to 3DCRT. Patient stratification into groups, depending on the benefit received from IMRT, is readily observed when plotting Vol./SA vs. PTV
Diameter while alternate plots do not clearly indicate a stratified subset of patients with improved treatment parameters.
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0.001, and 0.002, respectively. Thus, the stratification
rules given in Table 2 for conformity, V7, and V12 are
statistically significant (p < 0.05) while those for the
NT max dose are not; nevertheless, the use of IMRT
produced some improvement for all but one patient
with this endpoint. This was likely a direct result of1 2
0
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Decrease in maximum d
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V
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Figure 4 Normal Tissue Maximum Dose (PTV Only IMRT). Distribution of
PTV Only IMRT to 3DCRT. Patient stratification into groups, depending on the
Volume vs. PTV Diameter while alternate plots do not clearly indicate a stratifithe nature of IMRT treatments suggesting the NT
max dose would still benefit from IMRT, decreasing
patient complication rates.
In a report by QUANTEC, radiation dose-volume
effects in the brain were reviewed and complication rates
based on the 12Gy isodose volume were analyzed
[18]. The investigators of this study concluded that3 4 5
se up to 0.5%
ose by 0-4%
ose by 4-8%
ose by >8%
ameter, cm
patient improvements regarding the max dose to NT when comparing
benefit received from IMRT, is readily observed when plotting PTV
ed subset of patients with improved treatment parameters.
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Figure 5 Normal Tissue 7Gy Isodose Volume (OAR Low IMRT). Distribution of patient improvements regarding the volume of NT receiving 7Gy
when comparing OAR Low IMRT to 3DCRT. Patient stratification into groups, depending on the benefit received from IMRT, is readily observed when
plotting PTV Volume vs. PTV Diameter while alternate plots do not clearly indicate a stratified subset of patients with improved treatment parameters.
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NT is irradiated with >12Gy. IMRT achieves a
decrease in V12 with the stratified patients in Table 2
showing significant NT sparing effects. In fact, the
predicted benefits for the 7 and 12Gy isodose volumes of1 2
0
5
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20
25
30
Increase in V12Gy up to 1.
Decrease in V12Gy by 0-0
Decrease in V12Gy by 0.5
Decrease in V12Gy by >1.
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Figure 6 Normal Tissue 12Gy Isodose Volume (OAR Low IMRT). Distrib
12Gy when comparing OAR Low IMRT to 3DCRT. Patient stratification into
observed when plotting PTV Volume vs. PTV Diameter while alternate plots
treatment parameters.1.0 - 7.952 cc and −0.024 - 3.704 cc, respectively,
translate to considerable decreases in the probability of
radiation-induced brain injury post-SRS when interpreting
the results from the QUANTEC study [18]. In this publi-
cation, probabilities for radiation necrosis as a function of3 4 5
45 cm3
.5 cm3
-1.5 cm3
5 cm3
ameter, cm
ution of patient improvements regarding the volume of NT receiving
groups, depending on the benefit received from IMRT, is readily
do not clearly indicate a stratified subset of patients with improved
Table 2 PTV stratification rules
Characteristics of potential benefit with IMRT
PTV conformity NT max dose 7Gy isodose vol. 12Gy isodose vol.
PTV stratification rules Diameter <2.25 cm >2.5 cm >3.0 cm >2.9 cm
Volume N/A N/A >5.0 cc N/A
Vol./SA <0.25 cm N/A N/A N/A
Predicted improvement −0.06-0.68 −0.5-12.3 % 1.0-7.952 cc −0.024-3.704 cc
PTV stratification rules and predicted improvements for patient benefit with the use of IMRT for the treatment of AVMs. The predicted improvements are the ranges
obtained within this study for patients whose lesion characteristics satisfy the rules concerning each dosimetric parameter stated above. Within these rules, the boxes
labeled “N/A” for the corresponding PTV characteristic depict no clear boundary defining patient benefit resulting in the inability for patient stratification to be achieved.
Table 3 IMRT stratification of Spetzler-Martin grading
scheme
AVM grade Size Eloquence Venous
drainage
IMRT recommendation
1 1 0 0 PTV only
2 1 1 0 PTV only
1 0 1 PTV only
2 0 0 OAR low
3 1 1 1 PTV only
2 1 0 PTV only
2 0 1 OAR low
3 0 0 OAR low
4 2 1 1 PTV only
3 1 0 OAR low
3 0 1 OAR low
5 3 1 1 OAR low
The recommended IMRT plan type per Spetzler-Martin grade combination
is shown.
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concerning different isodose volumes: 10Gy, 12Gy,
and the treatment volume. However, only two data sets
relating symptomatic injury to the 12Gy isodose volume
are of interest: the Korytko 2006 and the Flickinger 1997
results. Each data set represents substantially different
variations in radiation necrosis with the 12Gy isodose
volume that, when simplified through averaging the slopes
of the linear portions of the plot, amount to a 0.6%/cc and
2.5%/cc increase in incidence of complications for the
Flickinger and Korytko studies, respectively. Comparing
this with the 12Gy isodose volume decreases attained with
IMRT (i.e. multiplying 0.6%/cc and 2.5%/cc with the
lower and upper limits on the V12 benefits, respectively),
the probability of symptomatic radiation injury in the
stratified subset of patients may be decreased by 0–9.3%.
Although these improvements appear promising, they are
simply a projected change in the incidence of brain injury
obtained through theoretical calculations and true benefit
can only be established with a clinical follow-up study.
Table 3 then translates the stratification rules from Table 2
into simple recommendations for the ideal IMRT planning
technique dependent upon the Spetzler-Martin Grade
determined at the time of diagnosis [20]. The key aspects of
each AVM grade that determine the corresponding IMRT
recommendation are size and eloquence. If an AVM is situ-
ated in an eloquent part of the brain or is of a small size
(diameter < 2.5 cm and small Vol./SA ratio) then PTV Only
IMRT is recommended; however, if the AVM is of a large
size (diameter >2.5 cm) and not eloquently located then
OAR Low IMRT is recommended. While OAR Medium
and OAR High plans provided comparable benefits to PTV
Only and OAR Low plans in some dosimetric aspects, they
routinely contained hotspots in the NT that exceeded
realistic restrictions on clinical treatment plans and,
as such, are not recommended for patient use. OAR
Low plans were found to provide the greatest benefit to
patients with large sized AVMs which is due to the larger
volume of NT that is irradiated in these plans together with
the fact that probability of symptomatic complications
following SRS is measured in terms of absolute volumes
spared. PTV Only plans, on the other hand, providedimprovements in PTV conformity for nearly all patients,
regardless of AVM size, which efficiently constrains the
prescription dose to the curvature of the PTV and spares
adjacent OARs of this high dose. The difference in the
mean values for all four dosimetric endpoints between
PTV Only and OAR Low IMRT plans were found to be
statistically significant (p < 0.05). These benefits provided
by the IMRT plans with the lowest weighting on OARs is
likely a result of the large of amount of fields that
have been utilized (typically >10) for the treatment of
small targets. This situation already maximizes the
OAR sparing so additional sparing then comes at the cost
of clipping the PTV beyond the conformal benefits
present in each IMRT plan. Thus, the advantages provided
by IMRT in these cases is in improvements in PTV
conformity, removing hotspots within NT while improving
the dose homogeneity across the PTV, and reducing NT
volumes receiving intermediate doses.
Conclusions
The work presented in this study indicates the potential
for significant conformity improvements with PTV Only
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http://www.ro-journal.com/content/9/1/73IMRT and/or dose reduction to NT at the 7 and 12Gy
isodoses with OAR Low IMRT as compared to 3DCRT.
Additionally, the likelihood of a patient receiving a
particular benefit from IMRT is a function of PTV
volume, diameter, and surface area. Using these three
characteristics, patients can be stratified into distinct
groups contingent upon the extent of benefits received
from IMRT. As a result, IMRT improvements over 3DCRT
can be readily attained on a case-by-case basis using the
associated treatment protocol; thus, reducing the risk of
symptomatic injury following radiotherapy.
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